MX2023008249A - Forma de dosificacion en tableta solida de ridinilazol. - Google Patents
Forma de dosificacion en tableta solida de ridinilazol.Info
- Publication number
- MX2023008249A MX2023008249A MX2023008249A MX2023008249A MX2023008249A MX 2023008249 A MX2023008249 A MX 2023008249A MX 2023008249 A MX2023008249 A MX 2023008249A MX 2023008249 A MX2023008249 A MX 2023008249A MX 2023008249 A MX2023008249 A MX 2023008249A
- Authority
- MX
- Mexico
- Prior art keywords
- ridinilazole
- solid tablet
- benzimidazole
- pyridin
- dosage form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2100470.0A GB202100470D0 (en) | 2021-01-14 | 2021-01-14 | Solid tablet dosage for of ridinilazole |
| PCT/IB2022/050311 WO2022153246A1 (en) | 2021-01-14 | 2022-01-14 | Solid tablet dosage form of ridinilazole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023008249A true MX2023008249A (es) | 2023-07-26 |
Family
ID=74679044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023008249A MX2023008249A (es) | 2021-01-14 | 2022-01-14 | Forma de dosificacion en tableta solida de ridinilazol. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12318487B2 (enExample) |
| EP (1) | EP4277604A1 (enExample) |
| JP (1) | JP2024503689A (enExample) |
| KR (1) | KR20230131253A (enExample) |
| CN (1) | CN116801867A (enExample) |
| AU (1) | AU2022207756B2 (enExample) |
| CA (1) | CA3145677A1 (enExample) |
| GB (1) | GB202100470D0 (enExample) |
| IL (1) | IL304354A (enExample) |
| MX (1) | MX2023008249A (enExample) |
| WO (1) | WO2022153246A1 (enExample) |
| ZA (1) | ZA202306739B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023213878A1 (en) * | 2022-05-04 | 2023-11-09 | Summit (Oxford) Limited | Solid tablet dosage form of ridinilazole |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824698A (en) | 1994-11-17 | 1998-10-20 | Hoffman-La Roche Inc. | Antibacterial dibenzimidazole derivatives |
| DE60131015T2 (de) | 2000-12-15 | 2008-07-10 | Vertex Pharmaceuticals Inc., Cambridge | Bakterielle gyrase-hemmer und deren verwendung |
| PL374191A1 (en) | 2002-06-13 | 2005-10-03 | Vertex Pharmaceuticals Incorporated | 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections |
| EP1558341A4 (en) | 2002-11-01 | 2010-09-08 | Paratek Pharm Innc | TRANSCRIPTION FACTOR MODULATING CONNECTIONS AND THEIR USE |
| JP2008504233A (ja) | 2004-04-23 | 2008-02-14 | パラテック ファーマシューティカルズ インコーポレイテッド | 転写因子調節化合物およびその使用法 |
| US7825154B2 (en) | 2005-08-12 | 2010-11-02 | The United States Of America As Represented By The Secretary Of The Army | Small molecule inhibitors of botulinum neurotoxins |
| JP2009514894A (ja) | 2005-11-07 | 2009-04-09 | バーテックス ファーマシューティカルズ インコーポレイテッド | ジャイレース阻害剤としてのベンズイミダゾール誘導体 |
| GB0612428D0 (en) | 2006-06-22 | 2006-08-02 | Prolysis Ltd | Antibacterial agents |
| CA2563690C (en) | 2006-10-12 | 2014-10-07 | Pharmascience Inc. | Pharmaceutical compositions comprising intra- and extra- granular fractions |
| FR2918566B1 (fr) * | 2007-07-11 | 2009-10-09 | Pierre Fabre Medicament Sa | Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine. |
| GB0821913D0 (en) * | 2008-12-02 | 2009-01-07 | Price & Co | Antibacterial compounds |
| ES2689107T3 (es) * | 2009-11-13 | 2018-11-08 | Astrazeneca Ab | Formulaciones de tabletas bicapa |
| WO2011151620A1 (en) | 2010-06-01 | 2011-12-08 | Summit Corporation Plc | Compounds for the treatment of clostridium difficile associated disease |
| ES2803556T3 (es) | 2010-06-01 | 2021-01-27 | Summit Oxford Ltd | Compuestos para el tratamiento de enfermedades asociadas a clostridium difficile |
| LT3250182T (lt) * | 2015-01-27 | 2023-07-10 | Janssen Pharmaceutica Nv | Dispersinės kompozicijos |
| CN118105392A (zh) * | 2017-04-28 | 2024-05-31 | 自由生物有限公司 | 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型 |
| WO2019068383A1 (en) * | 2017-10-05 | 2019-04-11 | Sandoz Ag | PROCESS FOR THE PREPARATION OF RIDINILAZOLE USING ACID ADDITION SALTS |
| KR20210033483A (ko) * | 2018-07-19 | 2021-03-26 | 다케다 야쿠힌 고교 가부시키가이샤 | Cdc7 억제제를 갖는 약제학적 조성물 |
| IL289453B2 (en) | 2019-07-17 | 2026-03-01 | Summit Oxford Ltd | Process for preparing ridinilazole and its crystalline forms |
-
2021
- 2021-01-14 GB GBGB2100470.0A patent/GB202100470D0/en not_active Ceased
-
2022
- 2022-01-14 CN CN202280010065.7A patent/CN116801867A/zh active Pending
- 2022-01-14 JP JP2023542844A patent/JP2024503689A/ja active Pending
- 2022-01-14 KR KR1020237027498A patent/KR20230131253A/ko active Pending
- 2022-01-14 EP EP22700441.3A patent/EP4277604A1/en active Pending
- 2022-01-14 US US17/576,242 patent/US12318487B2/en active Active
- 2022-01-14 WO PCT/IB2022/050311 patent/WO2022153246A1/en not_active Ceased
- 2022-01-14 AU AU2022207756A patent/AU2022207756B2/en active Active
- 2022-01-14 CA CA3145677A patent/CA3145677A1/en active Pending
- 2022-01-14 MX MX2023008249A patent/MX2023008249A/es unknown
-
2023
- 2023-06-30 ZA ZA2023/06739A patent/ZA202306739B/en unknown
- 2023-07-10 IL IL304354A patent/IL304354A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL304354A (en) | 2023-09-01 |
| WO2022153246A1 (en) | 2022-07-21 |
| AU2022207756B2 (en) | 2026-01-15 |
| ZA202306739B (en) | 2025-05-28 |
| JP2024503689A (ja) | 2024-01-26 |
| EP4277604A1 (en) | 2023-11-22 |
| GB202100470D0 (en) | 2021-03-03 |
| KR20230131253A (ko) | 2023-09-12 |
| AU2022207756A1 (en) | 2023-07-27 |
| US20220226249A1 (en) | 2022-07-21 |
| US12318487B2 (en) | 2025-06-03 |
| CN116801867A (zh) | 2023-09-22 |
| AU2022207756A9 (en) | 2024-05-09 |
| CA3145677A1 (en) | 2022-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20230066A (es) | Agonistas del glp-1 heterocíclicos | |
| PH12022552056A1 (en) | Heterocyclic glp-1 agonists | |
| MX2025002170A (es) | Inhibidores de kras g12c | |
| EP4306111A3 (en) | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | |
| ZA202200660B (en) | Process for the preparation of ridinilazole and crystalline forms thereof | |
| MX2021013993A (es) | Pirroles triciclicos condensados como moduladores de alfa-1 antitripsina. | |
| TN2020000159A1 (en) | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS | |
| IL326723A (en) | 2-(3,8-DIAZABICYCLO[3.2.1]OCTAN-3-YL)-1,3,5-TRIAZINE DERIVATIVES AS KRAS G12D INHIBITORS FOR CANCER TREATMENT | |
| NZ547615A (en) | Quinoline derivatives and use thereof as mycobacterial inhibitors | |
| WO2006107860A3 (en) | Dihydropyridine compounds and compositions for headaches | |
| MX2013005535A (es) | Compuesto de 3- (amino-aril) -piridina. | |
| JP2016536363A5 (enExample) | ||
| SI1487444T1 (sl) | Uporaba piridil-amidov kot inhibitorjev angiogeneze | |
| TW200640900A (en) | 1-(2h)-isoquinolone derivative | |
| MX2020011317A (es) | Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih. | |
| MX2018008095A (es) | Compuestos heterociclicos triciclicos condensados como inhibidores de integrasa del vih. | |
| PH12022551858A1 (en) | Novel heterocyclic compounds useful as aurora a selective inhibitors | |
| UA90763C2 (ru) | Производные пиразола, способ их получения, фармацевтический состав на их основе и их применение | |
| TN2016000556A1 (en) | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | |
| MY141024A (en) | Niacin receptor agonists, compositions containing such compounds and methods of treatment | |
| NO20080033L (no) | Kinolinderivater som NK3-antagonister | |
| TR199900732T2 (xx) | PDE IV inhibe eden 2-siyanoiminoimidazol t�revleri. | |
| MX2022007518A (es) | Derivados bencimidazol. | |
| MX2023008249A (es) | Forma de dosificacion en tableta solida de ridinilazol. | |
| PH12022551282A1 (en) | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use |